Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 11/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7474893 | 1.00 | ADRB3 (0.48) | ADRB3ADRB1ADRB2BCAT2ADRA1D | |
| SCHEMBL7466075 | 1.00 | ADRB3 (0.48) | ADRB3ADRB1ADRB2BCAT2ADRA1D | |
| SCHEMBL7804827 | 0.84 | RAB9A (0.42) | ADRB3ADRB1ADRB2ADRA1DCYP1A2 | |
| SCHEMBL7467581 | 0.84 | RAB9A (0.42) | ADRB3ADRB1ADRB2ADRA1DCYP1A2 | |
| SCHEMBL7458742 | 0.84 | RAB9A (0.42) | ADRB3ADRB1ADRB2ADRA1DCYP1A2 | |
| SCHEMBL7476838 | 0.83 | BCAT2 (0.47) | BCAT2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7460922 | 0.83 | BCAT2 (0.47) | BCAT2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5248171 | 0.83 | BCAT2 (0.68) | BCAT2CYP1A2CYP2D6 | |
| SCHEMBL4597974 | 0.80 | CTSL (0.47) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL10319930 | 0.80 | CTSL (0.47) | ADRB3ADRB1ADRB2ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0907635-B1 | HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL | SK CORP (KR) | 2002-09-25 | — | — | EP | disclosed |
| US-20010034365-A1 | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | CHOI YONG MOON (US) | 2001-10-25 | — | — | US | disclosed |
| US-6127412-A | TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS | SK CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6103759-A | COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SK CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034365-A1 | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | DDT, GRIK2, GABRD | ADRB3 1669/4885ADRB1 2339/4885ADRB2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.